[Comment] Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?
Annually, more than 950 000 people are diagnosed with gastric or oesophagogastric junction cancer1—the third most lethal cancer worldwide2—for which there is a considerable unmet clinical need. Blockade of immune checkpoints has been successfully integrated into standard treatment regimens for several solid tumours. 3 The ATTRACTION-2 study by Yoon-Koo Kang and colleagues4 in The Lancet is, to my knowledge, the first randomised, placebo-controlled, phase 3 trial of immune checkpoint blockade in gastrointestinal cancers.
Source: LANCET - Category: General Medicine Authors: Ian Chau Tags: Comment Source Type: research
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | General Medicine | Study